Conclusion
angina symptoms, RA, T2DM, angina
TYPE 2 DIABETES MELLITUS
Empagliflozin can be safely added as a metabolic modulator agent to existing antianginal medications in individuals with concurrent T2DM and RA to reduce angina symptoms and enhance exercise capacity with minimal side effects.The EMPT‐ANGINA randomized trial evaluated the effect of empagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, on angina symptoms and exercise capacity in patients with both type 2 diabetes mellitus (T2DM) and refractory angina (RA). Patients were divided into two groups: one received empagliflozin (
